Patent US4309188A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4309188A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for the clinical separation of α- and β-lipoproteins

Assignee: Symphar SA
•
Filing: 1980-03-17
•
Granted: 1982-01-05
•
Expires: 2000-03-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention relates to a separation method comprising the introduction of a sample of serum or plasma into a microcolumn containing a support which has a sulfated polysaccharide, preferably heparin, covalently bound to it so as to remove from said sample the β-lipoproteins by binding thereof to this ligand, followed by washing the microcolumn with a first pH buffered solution and collecting the eluant representing a first fraction containing the α-lipoprotein portion of the sample. Then the microcolumn is washed wth a second pH buffered solution so as to release the ligand-bound β-lipoproteins and to recover a second fraction containing the β-lipoprotein portion of the sample. Afterwards, it is possible to separately determine the α- and β-lipoprotein-cholesterol, as well as the respective α/β ratios of phospholipids, triglycerides and various apoproteines, and to calculate the respective ratios α/β, all useful as clinical diagnostic indexes and allowing to obtain a complete lipoprotein profiling. The invention also concerns a kit comprising in a transportable box all the implements and reagents duly prepared so as to easily and quickly carry out the above method.

Inventors

  • 👤 Craig L. Bentzen

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 11:43
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/92; G01N2800/00; G01N2800/04; G01N2800/044; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 155 words
A method for the clinical separation of α-lipoproteins from β-lipoproteins and for the determination of the ratio of α-lipoproteins to β-lipoproteins in serum or plasma free from added divalent cations, comprising introducing a sample of serum or plasma free from added divalent cations into a microcolumn containing heparin bound to agarose so as to remove from said sample the β-lipoproteins by binding thereof to this ligand, washing the microcolumn with a first pH-buffered solution free from added divalent cations and collecting the eluant as a first fraction containing the α-lipoprotein portion of the sample, subsequently washing the microcolumn with a second pH-buffered solution free from added divalent cations that releases the ligand-bound β-lipoproteins and collecting the eluant as a second fraction containing the β-lipoprotein portion of the sample, analyzing the first fraction for α-lipoprotein, analyzing the second fraction for β-lipoprotein, and using said analyses to calculate the ratio of α-lipoproteins and β-lipoproteins in said sample.
Claim 2
Independent Claim 155 words
A method for the clinical separation of α-lipoproteins from β-lipoproteins and for the determination of the ratio of α-lipoproteins to β-lipoproteins in serum or plasma free from added divalent cations, comprising introducing a sample of serum or plasma free from added divalent cations into a microcolumn containing heparin bound to agarose so as to remove from said sample the β-lipoproteins by binding thereof to this ligand, washing the microcolumn with a first pH-buffered solution free from added divalent cations and collecting the eluant as a first fraction containing the α-lipoprotein portion of the sample, subsequently washing the microcolumn with a second pH-buffered solution free from added divalent cations that releases the ligand-bound β-lipoproteins and collecting the eluant as a second fraction containing the β-lipoprotein portion of the sample, analyzing the first fraction for α-lipoprotein, analyzing the second fraction for β-lipoprotein, and using said analyses to calculate the ratio of α-lipoproteins and β-lipoproteins in said sample.
Claim 3
Dependent Claim 24 words
A method as claimed in claim 1, in which there is about 0.6 to 1% by weight of heparin covalently bound to said agarose.
Claim 4
Dependent Claim 19 words
A method as claimed in claim 1, and analyzing said first and second fractions for α-lipoprotein-cholesterol and β-lipoprotein-cholesterol, respectively.
Claim 5
Dependent Claim 19 words
A method as claimed in claim 1, and analyzing said first and second solutions for α-lipoprotein-phospholipid and β-lipoprotein-phospholipid, respectively.
Claim 6
Dependent Claim 19 words
A method as claimed in claim 1, and analyzing said first and second solutions for α-lipoprotein-triglycerides and β-lipoprotein-triglycerides, respectively.
Claim 7
Dependent Claim 17 words
A method as claimed in claim 1, in which said sample is about 0.5 ml in volume.
Claim 8
Dependent Claim 39 words
A method according to claim 1, in which said first and second solutions contain respectively 0.140 to 0.165 M and 0.5 to 1.5 M sodium chloride, as well as buffer salts producing a pH range of 6.0 to 6.5.
Claim 9
Dependent Claim 27 words
A method according to claim 7, in which said first solution has a pH of about 6.2 and said second solution has a pH of about 6.5.
Claim 10
Dependent Claim 49 words
Kit for carrying out the separation method according to claim 1, comprising in a transportable box, a rack holder, a number of microcolumns containing heparin bound to agarose free from added divalent cations, and containers containing the respectively first and second pH buffered solutions free from added divalent cations.
Claim 11
Dependent Claim 23 words
Kit according to claim 9, in which the microcolumns are of a type comprising an inert filter for holding the agarose in position.
Claim 12
Dependent Claim 21 words
Kit according to claim 9, in which about 0.6 to 1.0% in weight of heparin is covalently bound to the agarose.
Claim 13
Dependent Claim 43 words
Kit according to claim 9, in which said first and second buffered solutions contain respectively 0.140 to 0.165 M and 0.5 to 1.5 M sodium chloride, as well as buffer salts, preferably of sodium phosphate, producing a pH range of 6.0 to 6.5.
Claim 14
Dependent Claim 17 words
Kit according to claim 9 further comprising containers containing reagents for performing cholesterol, phospholipids and/or triglycerides determinations.

References Cited (Backward Citations)

US4039285A Cited
US4103685A Cited
US4096136A Cited
US4178439A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-01-04 1985-07-06 1986-01-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-01-04 1989-07-06 1990-01-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-01-04 1993-07-06 1994-01-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag